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Summary
OBJECTIVE: To assess the presence of Mycoplasma pneu-
moniae-associated encephalitis in children in Switzerland
and its likely pathogenesis.
METHODS: M. pneumoniae-associated encephalitis cases
seen at a single-centre during 2010–2013 were reviewed,
and the Swiss Paediatric Surveillance Unit (SPSU) pro-
spectively conducted a nationwide surveillance
2013–2015. Case definition included confirmed, probable
and possible cases.
RESULTS: Seven patients (median age 8.7 years, range
4.7–10.1 years) with confirmed or possible M. pneumo-
niae-associated encephalitis were observed. All patients
manifested prodromal respiratory symptoms over at least 5
days and five out of the six who had a chest radiograph,
showed pulmonary infiltrates. M. pneumoniae DNA in
cerebrospinal fluid was negative in all patients. In-
trathecally synthesised M. pneumoniae-specific immuno-
globulin (IgM and IgG) were investigated and found posit-
ive in one patient (confirmed case). M. pneumoniae DNA
in respiratory specimens and/or M. pneumoniae-specific
IgM and IgG in serum were detected in the other six pa-
tients (possible cases). One confirmed and two possible
cases had neurological sequelae at 4–19 months follow-up.
CONCLUSION: The lack of detectable M. pneumoniae
DNA in cerebrospinal fluid of our encephalitis patients
suggests a likely immune-mediated pathogenesis ignited by
a respiratory inflammatory process including pneumonia.
Key words: children; encephalitis; epidemiology;
Mycoplasma pneumoniae; pneumonia
Introduction
Encephalitis is the most severe extrapulmonary manifest-
ation of Mycoplasma pneumoniae infection [1]. Its patho-
genesis is not understood [2]. Detecting M. pneumoniae in
the central nervous system (CNS) may be most straight-
forward to confirm M. pneumoniae-associated encephalitis
[3]. However, two large recent national encephalitis studies
were unable to detect M. pneumoniae DNA by means of
polymerase chain reaction (PCR) in cerebrospinal fluid
(CSF) (United Kingdom 2005–2006 [4] and France, 2007
[5]). In contrast, another national encephalitis study repor-
ted M. pneumoniae as a possible cause, detected either by
serology or positive PCR in respiratory specimens, in 6%
(96/1570; US, 1998–2005 [6]), compared with two cases
confirmed by PCR in CSF (0.1%). Thus, CNS infection or
immune-mediated pathology are debated. These divergent
pathogenetic hypotheses create uncertainty in diagnostic
procedures and lead to differences in case definition criteria
[7].
We aimed to assess the presence of paediatric M. pneumo-
niae-associated encephalitis in Switzerland and its likely
pathogenesis.
Methods
Study design
Preparatory study
To evaluate whether a nationwide surveillance was worth
being conducted we retrospectively reviewed paediatric M.
pneumoniae-associated encephalitis cases in the frame of
a community-acquired pneumonia study at the University
Children’s Hospital of Zurich [8] between July 1, 2010 and
June 30, 2013.
National prospective surveillance study
Between July 1, 2013 and June 30, 2015, the Swiss Pae-
diatric Surveillance Unit (SPSU), a national network of 33
hospitals [9, 10], prospectively collected reports of paedi-
atric M. pneumoniae-associated encephalitis. Anonymised
demographic, clinical, and microbiological data were sent
to the SPSU central, which forwarded the forms to the prin-
cipal investigator who verified the case definition. An out-
come evaluation questionnaire was dispatched to the caring
practitioner half a year after case presentation.
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Mycoplasma pneumoniae-associated encephalitis case
definition
Children ≤16 years of age fulfilling (1) the clinical case
definition for acute encephalitis (suppl. table S1) [11] and
(2) the aetiological case definition for acute encephalitis
caused by M. pneumoniae [3], i.e., (2a) “confirmed” (de-
tection of M. pneumoniae by PCR in CSF or of intrathecal
synthesis of specific antibodies), (2b) “probable” (≥4-fold
rise in specific serum antibody titre), or (2c) “possible” (de-
tection of M. pneumoniae by PCR in respiratory specimens
and/or single raised specific serum antibody titre), were
considered cases.
Results
One “confirmed” and three “possible” paediatric M. pneu-
moniae-associated encephalitis cases were observed during
the 3-year preparatory study and three “possible” cases
during the 2-year national prospective surveillance study
(table 1). All patients were male (median age 8.7 years,
range 4.7–10.1). Pleocytosis was present in six cases (86%;
Table 1: Characteristics of seven cases with paediatric Mycoplasma pneumoniae-associated encephalitis.
Aetiological case definition for M. pneumoniae-associated
encephalitis1
CSF RS Serum
No. Inclusion Age (y),
sex
Prodrome (d),
symptoms
Chest
radiograph
PCR Antibodies
(IgM, IgG)
PCR Antibodies
(IgM, IgG)
Case
definition [3]
Treatment
(duration [d])
Outcome
(last follow-
up [m])
Preparatory study (2010–2013)
1 12/2010 4.7, M 5
Fever, rhinitis,
pharyngitis,
conjunctivitis,
mucositis,
erythema
multiforme, cervical
adenopathy2
Infiltrate – ND – +3 Possible Cefaclorum (3)
Aciclovir (3)
Ceftriaxone (3)
Clarithromycin (7)
IVIg (1)
Prednisolone (9)
Normal (4)
2 01/2011 8.3, M 6
Fever, cough,
rhinitis
Infiltrate – ND + +3 Possible Ceftriaxone (3)
Doxycycline (7)
Normal (2)
3 12/2011 10.1, M 5
Fever, cough
ND – ND + +3 Possible Aciclovir (3)
Ceftriaxone (3)
Normal (1)
4 [18] 11/2012 8.7, M 21
Cough, rhinitis
Infiltrate – +
(intrathecal
synthesis)4
+ + Confirmed Doxycycline (7)
IVIg (1)
Prednisolone (5)
Mild
residual
hemiparesis
of the upper
extremities,
incomplete
facial palsy
(19)
National prospective surveillance study (2013–2015)
5 04/2014 9.3, M 15
Fever, cough,
rhinitis
Infiltrate – ND + ND Possible Aciclovir (1)
Ceftriaxone (1)
Ciprofloxacin (1)
Vancomycin (1)
Moxifloxacin (8)
Optic disc
swelling (6)
6 09/2014 7.8, M 9
Fever, cough
Infiltrate – ND + ND Possible Amoxicillin (3)
Clarithromycin (3)
Aciclovir (3)
Ceftriaxone (3)
Ciprofloxacin (14)
Aggressive
behavior,
headache
(4)
7 05/2015 8.8, M 7
Fever, rhinitis,
pharyngitis
– – ND + + Possible Acyclovir (3)
Ceftriaxone (1)
Methylprednisolone
(3)
Prednisolone (14)
Normal
(hospital
discharge)
CSF = cerebrospinal fluid; Ig = immunoglobulin; IVIg = intravenous immunoglobulin; ND = not done; PCR = polymerase chain reaction; PS = pharyngeal swab; RS =
respiratory specimens.
1 No case met confirmed or probable aetiological case definition for another infectious agent [3]; negative investigations as follows:
Case 1: PCR CSF: Herpes simplex virus 1/2, enteroviruses; PCR PS: Influenza A, respiratory syncytial virus; Serology: Herpes simplex virus 1/2; CSF and blood:
conventional bacterial cultures;
Case 2: PCR PS: respiratory viruses (multiplex PCR); PS antigen test: Streptococcus pneumoniae; Serology: tick-borne encephalitis; CSF and blood: conventional
bacterial cultures; tuberculin skin test;
Case 3: PCR CSF: Herpes simplex virus 1/2, enteroviruses; Serology: tick-borne encephalitis; CSF and blood: conventional bacterial cultures;
Case 4: PCR CSF: Herpes simplex virus 1/2, enteroviruses, Epstein-Barr virus; PCR PS: Influenza A/B; Serology: Borrelia burgdorferi; CSF and blood: conventional
bacterial cultures;
Case 5–7: no other potential aetiological agents reported, but no further information according to study design.
2 Patient 1 developed pericardial effusion during the course of the disease. PCR assays of pericardial fluid and tissue biopsy for M. pneumoniae were negative.
3 Persisting elevated IgM and IgG titres over 4 weeks (patient 1), 8 weeks (patient 2), or 6 weeks (patient 3).
4 Three-isotype immunoglobulin reaction (IgM, IgG, and IgA).
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median cell number 30/ul, range 8–96) and neuroimaging
was consistent with encephalitis in five cases (71%; suppl.
table S1). Preceding respiratory symptoms were reported
in all patients (median duration 7 days, range 5–21 days)
and pneumonia was radiologically confirmed in five of six
patients (83%). M. pneumoniae DNA was detected in the
respiratory specimens of six patients, but not in CSF, and
M. pneumoniae-specific immunoglobulin (IgM and IgG) in
serum of all five tested patients and in CSF of one tested
patient. Three patients (43%) still had neurological signs
and symptoms at 4–19 months follow-up (table 1).
Discussion
Here, we have documented for the first time the presence
of paediatric M. pneumoniae-associated encephalitis in
Switzerland and gathered indications of an immune-medi-
ated process.
Our three M. pneumoniae-associated encephalitis cases ob-
served during the 2-year national surveillance represent an
estimated yearly incidence of 0.09 cases per 100 000 pop-
ulation ≤19 years of age [12], although underreporting is
likely. Nevertheless, the figure is comparable to that in Fin-
land, estimated after a national surveillance in 1993–1994
(0.1 cases per 100 000) [13]. The incidence, however, de-
pends on the presence or absence of epidemics. Indeed,
we retrospectively identified four patients in a single-centre
over a prior 3-year period and three of them coincided with
the M. pneumoniae epidemic in Europe from 2010–2011
[8, 14].
M. pneumoniae was found as the cause of 9% (84/906;
USA, 1998–2006 [15]) and 31% (50/159; Canada,
1994–1998 [16]) of cases of paediatric encephalitis,
whereby 2% (1/62) [15] and 12% (6/50) [16] of the cases,
respectively, were confirmed by PCR in CSF. The yearly
incidence of paediatric encephalitis in developed countries
is about 10.5 cases per 100 000 children [13]. Since no data
on paediatric encephalitis exist for Switzerland we cannot
estimate the relative frequency of our M. pneumoniae-as-
sociated encephalitis cases.
We found no M. pneumoniae DNA in CSF of any patient
but it was present in throat specimens of all patients except
one, and specific serum antibodies were found in all pa-
tients tested. This suggests that their encephalitis was likely
immune-mediated following respiratory infection. Indeed,
all patients had prodromal respiratory symptoms over at
least 5 days. Interestingly, a recent study [17] reported that
M. pneumoniae-associated encephalitis patients with neg-
ative PCR for M. pneumoniae in CSF showed radiologic-
al signs of pneumonia with infiltrates on chest radiograph
more frequently than patients with positive PCR in CSF
(77% vs 33%). We found infiltrates on chest radiograph in
83%.
Pleocytosis was present in most of our patients and
neuroimaging was compatible with an inflammatory pro-
cess in 71%. This further underscores the likelihood of an
immune-mediated pathogenesis in our M. pneumoniae-as-
sociated encephalitis cases, which was proven by the detec-
tion of an intrathecal antibody synthesis in one investigated
patient (patient 4) [18]. Antibodies against M. pneumoni-
ae have been shown to cross-react with galactocerebros-
ide (GalC) [19]. GalC is a major glycolipid antigen in the
myelin of both the peripheral and central nervous systems.
We previously demonstrated, in this specific case, antibod-
ies against GalC in serum and CSF [20], which suggests
that these antibodies are involved in the development of M.
pneumoniae-associated encephalitis [2]. Intriguingly, one
patient showed extensive extrapulmonary multiorgan in-
flammation with additional involvement of skin and heart
(patient 1), which required prolonged anti-inflammatory
treatment.
In conclusion, we suspect an immune-mediated process in
our observed M. pneumoniae-associated encephalitis cases.
Pneumonia may be an indicator for the remote inflam-
matory process. The association of encephalitis with M.
pneumoniae may be increasingly established by expanding
diagnostic procedures through the analysis of intrathecal
antibodies.
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Supplementary table
Table S1: Clinical case definitions for seven cases with paediatric Mycoplasma pneumoniae-associated encephalitis.
No. Inclusion Age (y),
sex
Major
criterion [11]:
Minor criteria (≥3 required) [11]:
Fever New onset of
neurological
signs and
symptoms
Pleocytosis
(CSF WBC ≥5/
ul)
CSF WBC
count (cells/ul)
Abnormality on
neuroimaging
suggestive of
encephalitis
Abnormality on
EEG
consistent with
encephalitis
Preparatory study (2010–2013)
1 12/2010 4.7, M Decreased
level of
consciousness
+ Ataxia − 3 + (MRI) +
2 01/2011 8.3, M Decreased
level of
consciousness
+ Ataxia
Cerebellar
mutism
Nuchal rigidity
Headache
+ 38 − +
3 12/2011 10.1, M Decreased
level of
consciousness
+ Altered verbal
communication
Incontinence
(urine and stool)
Nuchal rigidity
Headache
+ 96 + (MRI) +
4 [18] 11/2012 8.7, M Coma − Ataxia
Ophthalmoplegia
Hemiplegia
Nuchal rigidity
Headache
+ 11 + (MRI) +
National prospective surveillance study (2013–2015)
5 04/2014 9.3, M Decreased
level of
consciousness
+ Nuchal rigidity
Headache
Vomiting
+ 8 + (MRI, CT) ND
6 09/2014 7.8, M Decreased
level of
consciousness
Personality
change
+ Nuchal rigidity
Headache
Vomiting
(+) 25 (traumatic) – +
7 05/2015 8.8, M Decreased
level of
consciousness
+ Ataxia
Dysarthria
Headache
Vomiting
+ 35 + (MRI) ND
CSF = cerebrospinal fluid; CT = computed tomography; EEG = electroencephalography; MRI = magnetic resonance imaging; ND = not done; WBC = white blood cell.
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